Anagliptin vs Saxagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Anagliptin · Suiny
Marketed by Sanwa Kagaku Kenkyusho and partners
NCT01529541 · Phase 3 · completed
The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.
Next expected readout: March 2027 · NCT07442006 (registry estimate)
Reported efficacy
The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)
Result source: NCT01529528
Saxagliptin · Onglyza
Rights held by AstraZeneca and partners; US product discontinued
NCT00121667 · Phase 3 · completed
Large randomized, double-blind, placebo-controlled phase 3 trial (743 treated participants across three saxagliptin doses and one placebo arm, all on background metformin). The primary endpoint was change from baseline in hemoglobin A1c at Week 24, an accepted hard glycemic measure for type 2 diabetes, and every saxagliptin dose showed a statistically significant improvement versus placebo (adjusted differences of -0.73, -0.83, and -0.72 percentage points, each p<0.0001). Because the trial was adequately powered, double-blind, and placebo-controlled, and the primary comparison was met, this is strong evidence for saxagliptin's efficacy.
Next expected readout: February 2027 · NCT02969798 (registry estimate)
Reported efficacy
Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Baseline and Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Baseline, Week 24): Saxagliptin 2.5 mg + Metformin — Baseline Mean: 8.08 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: -0.59 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 5 mg + Metformin — Baseline Mean: 8.07 percentage of glycosylated hemoglobins (Standard Error 0.06); Adjusted Mean Change from Baseline: -0.69 percentage of glycosylated hemoglobins (Standard Error 0.07) | Saxagliptin 10 mg + Metformin — Baseline Mean: 7.98 percentage of glycosylated hemoglobins (Standard Error 0.08); Adjusted Mean Change from Baseline: -0.58 percentage of glycosylated hemoglobins (Standard Error 0.07) vs Placebo+ Metformin — Baseline Mean: 8.06 percentage of glycosylated hemoglobins (Standard Error 0.07); Adjusted Mean Change from Baseline: 0.13 percentage of glycosylated hemoglobins (Standard Error 0.07) (met)
Result source: NCT00121667
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anagliptin | Saxagliptin |
|---|---|---|
| HbA1c, change | -0.5% vs 0.2%a−0.7 vs placeboNCT015295282 other results
| -0.7% vs -0.3%−0.4 vs placeboNCT0075758819 other results
|
| Body weight, change (kg) | —Not posted · NCT01529528 | -1.9 vs -0.4−1.5 vs placeboNCT016463207 other results
|
| HbA1c below 7% | —Not posted · NCT01529528 | 44.4% vs 16.6%+27.8 vs placeboNCT0012166715 other results
|
| Fasting plasma glucose, change | —Not posted · NCT01529528 | -0.6 vs -0.3−0.2 vs placeboNCT0075758811 other results
|
| 3-point MACE (% with event) | —Not posted · NCT01529528 | 7.4% vs 7.4%±0 vs placeboNCT01107886 |
HbA1c, change
- Anagliptin
- -0.5% vs 0.2%a−0.7 vs placeboNCT01529528
2 other results
- -0.5% vs 0.2% NCT01529528
- -0.8% vs -0.8% NCT01529541
- Saxagliptin
- -0.7% vs -0.3%−0.4 vs placeboNCT00757588
19 other results
- 7.1% vs 7.5% NCT00661362
- -0.5% vs -0.2% NCT01619059
- -0.8% vs -0.1% NCT01646320
- -0.7% vs -0.1% NCT01128153
- 0.1% vs 0.5% NCT03199053
- -0.7% vs 0.6% NCT01204775
- -1% vs 0.9% NCT01434186
- -1.4% vs -1.0% NCT02419612
- -1.7% vs -1.5% NCT02551874
- -1.0% vs -0.7% NCT02681094
- -1.4% vs -1.1% NCT02284893
- -0.2% vs -0.7% NCT03199053
- 0.1% vs -0.7% NCT03199053
- -0.8% vs -1.0% NCT02471404
- -1.2% vs -1.0% NCT02471404
- -0.8% vs -0.8% NCT02243176
- -0.8% vs -0.8% NCT02243176
- -0.5% vs -0.4% NCT01006590
- -0.4% vs -0.6% NCT01006603
Body weight, change (kg)
- Anagliptin
- —Not posted · NCT01529528
- Saxagliptin
- -1.9 vs -0.4−1.5 vs placeboNCT01646320
7 other results
- -3.1 vs 0.9 NCT02419612
- -1.9 vs -0.5 NCT02284893
- -1.5 vs 2.1 NCT02551874
- -2.0 vs -0.4 NCT02681094
- -3.5 vs 1.8 NCT02471404
- -3.1 vs 1.8 NCT02471404
- -1.4 vs -2.0 NCT02243176
HbA1c below 7%
- Anagliptin
- —Not posted · NCT01529528
- Saxagliptin
- 44.4% vs 16.6%+27.8 vs placeboNCT00121667
15 other results
- 41.1% vs 23.9% NCT00121641
- 43.5% vs 16.6% NCT00121667
- 37.9% vs 23.9% NCT00121641
- 22.1% vs 13.3% NCT00918879
- 45.8% vs 28.8% NCT00698932
- 37.1% vs 16.6% NCT00121667
- 35% vs 23.9% NCT00121641
- 37.5% vs 24.2% NCT00885378
- 21.3% vs 10% NCT03199053
- 36.7% vs 13.3% NCT01646320
- 21.4% vs 11.7% NCT02419612
- 44.3% vs 34.3% NCT02419612
- 37.3% vs 25.1% NCT02284893
- 37.2% vs 26.1% NCT00960076
- 38.3% vs 41.5% NCT02243176
Fasting plasma glucose, change
- Anagliptin
- —Not posted · NCT01529528
- Saxagliptin
- -0.6 vs -0.3−0.2 vs placeboNCT00757588
11 other results
- -0.5 vs -0.3 NCT01619059
- 0.1 vs 0.2 NCT03199053
- -1.8 vs -0.3 NCT01646320
- -0.3 vs 0.1 NCT01128153
- -1.8 vs -0.6 NCT02284893
- -2.4 vs -1.0 NCT03199053
- -0.6 vs -1.0 NCT03199053
- -1.6 vs -1.5 NCT02471404
- -0.7 vs -1.3 NCT01006603
- -2.1 vs -1.5 NCT02471404
- -1.0 vs -1.0 NCT02243176
3-point MACE (% with event)
- Anagliptin
- —Not posted · NCT01529528
- Saxagliptin
- 7.4% vs 7.4%±0 vs placeboNCT01107886
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Anagliptin: 0 of 4 rows · Saxagliptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Anagliptin | Saxagliptin |
|---|---|---|
| Dropout rate | — | 22.7%10 mga NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results25.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 22.9%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 29.6%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 35.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 28.4%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 0% NCT02024477 · Phase 4 · registry result, not featured evidence 10.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 4.5%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 5.7% NCT02243176 · Phase 4 · registry result, not featured evidence 17.1% NCT01608724 · Phase 4 · registry result, not featured evidence 2.4% NCT01107886 · Phase 4 · registry result, not featured evidence 19.7%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 19% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 5.7%Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 7.5%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 8.6% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 8.2% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 25% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 6.8%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.5%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 7.2%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 12.4% NCT01128153 · Phase 3 · registry result, not featured evidence 5.8% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 61.4% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5.6%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 4.3%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 11.8%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 50.6% NCT00614939 · Phase 3 · registry result, not featured evidence 10.8%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 15%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 7.7%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 10.2%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | — | 2.8%10 mga NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results3.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.6%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.1%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.8%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.9%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 — NCT02024477 · Phase 4 · registry result, not featured evidence 2.2%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 0.3%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 0.8% NCT02243176 · Phase 4 · registry result, not featured evidence 2% NCT01608724 · Phase 4 · registry result, not featured evidence — NCT01107886 · Phase 4 · registry result, not featured evidence 4.2%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 1.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 0.4%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence — NCT02551874 · Phase 3 · registry result, not featured evidence · combination 3.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 0.4% NCT02284893 · Phase 3 · registry result, not featured evidence · combination — NCT01204775 · Phase 3 · registry result, not featured evidence — NCT01434186 · Phase 3 · registry result, not featured evidence —5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination 1.7%Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination —DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination 1.9%Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination — NCT01606007 · Phase 3 · registry result, not featured evidence · combination 0.8% NCT01128153 · Phase 3 · registry result, not featured evidence 0.7% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 2.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00918879 · Phase 3 · registry result, not featured evidence —5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 5.9% NCT00614939 · Phase 3 · registry result, not featured evidence —2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination —5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 0%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 1.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | — | 12.2%10 mga NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 43 more results14.1%5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 12%2.5 mg NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%10 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 17%5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.8%2.5 mg NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.8% NCT02024477 · Phase 4 · registry result, not featured evidence 12.5%10mg NCT02471404 · Phase 4 · registry result, not featured evidence 7.1%5mg and 10mg NCT02471404 · Phase 4 · registry result, not featured evidence · combination 2.1% NCT02243176 · Phase 4 · registry result, not featured evidence 1.8% NCT01608724 · Phase 4 · registry result, not featured evidence 25.5% NCT01107886 · Phase 4 · registry result, not featured evidence 11.4%5 mg NCT01006603 · Phase 4 · registry result, not featured evidence 4.1% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 3.8%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 0%5 mg NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.3%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 1.6%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence 4.9%2.5 mg NCT03199053 · Phase 3 · registry result, not featured evidence —Saxagliptin NCT03199053 · Phase 3 · registry result, not featured evidence · background therapy 12.8%dapagliflozin 10 mg, saxagliptin 5 mg NCT02419612 · Phase 3 · registry result, not featured evidence 6.2% NCT02551874 · Phase 3 · registry result, not featured evidence · combination 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on 3.9% NCT02284893 · Phase 3 · registry result, not featured evidence · combination 0% NCT01204775 · Phase 3 · registry result, not featured evidence 0% NCT01434186 · Phase 3 · registry result, not featured evidence 5.1%5 mg QD NCT02104804 · Phase 3 · registry result, not featured evidence · combination —Saxagliptin Plus Insulin NCT02104804 · Phase 3 · registry result, not featured evidence · combination 4.4%DAPA + SAXA + MET NCT01646320 · Phase 3 · registry result, not featured evidence · combination —Dapa+Saxa+Met NCT01646320 · Phase 3 · registry result, not featured evidence · combination 4.6%5 mg NCT01619059 · Phase 3 · registry result, not featured evidence · combination 1.1% NCT01606007 · Phase 3 · registry result, not featured evidence · combination 2.3% NCT01128153 · Phase 3 · registry result, not featured evidence 0% NCT00960076 · Phase 3 · registry result, not featured evidence · combination 12.6% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 0%5 mg NCT00918879 · Phase 3 · registry result, not featured evidence 2.2%5 mg + Metformin XR 1500 mg NCT00918138 · Phase 3 · registry result, not featured evidence · combination 8.2%5 mg NCT00757588 · Phase 3 · registry result, not featured evidence · combination 27.1% NCT00614939 · Phase 3 · registry result, not featured evidence 1.4%2.5 mg NCT00885378 · Phase 3 · registry result, not featured evidence · combination 5%5 mg NCT00374907 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00698932 · Phase 3 · registry result, not featured evidence 2.8%5 mg NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | — | 10 mga influenza 15.5% (placebo 15.1%) nasopharyngitis 15.5% (placebo 14%) headache 13.3% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 37 more results5 mg influenza 16.2% (placebo 15.1%) nasopharyngitis 14.7% (placebo 14%) arthralgia 10.5% (placebo 6.7%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 15.1% (placebo 12.8%) nasopharyngitis 14.6% (placebo 14%) headache 14.1% (placebo 12.3%) NCT00121667 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg arthralgia 16.3% (placebo 7.4%) headache 16.3% (placebo 16.8%) influenza 15.3% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg upper respiratory tract infection 15.1% (placebo 15.8%) urinary tract infection 13.2% (placebo 8.4%) headache 12.3% (placebo 16.8%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg diarrhoea 13.7% (placebo 8.4%) upper respiratory tract infection 11.8% (placebo 15.8%) influenza 10.8% (placebo 6.3%) NCT00121641 · Phase 3 · combination · Type 2 Diabetes · phase 3 5mg and 10mg nasopharyngitis 9.9% NCT02471404 · Phase 4 · registry result, not featured evidence · combination hyperlipidaemia 6.2% hyperlipidaemia 3.7% abdominal distension 1.2% NCT02243176 · Phase 4 · registry result, not featured evidence upper respiratory tract infection 2.7% dizziness 2.6% NCT01608724 · Phase 4 · registry result, not featured evidence diabetes mellitus 6.5% (placebo 8.1%) dizziness 4.5% (placebo 4.2%) hypertension 4.2% (placebo 3.9%) NCT01107886 · Phase 4 · registry result, not featured evidence 5 mg nasopharyngitis 6.4% arthralgia 4.7% diarrhoea 4.2% NCT01006603 · Phase 4 · registry result, not featured evidence hypoglycaemia 6.8% diarrhoea 6.1% nasopharyngitis 5.4% NCT01006590 · Phase 4 · registry result, not featured evidence · add on 5 mg toothache 7.7% (placebo 0%) acne 3.8% (placebo 0%) animal bite 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg aphthous ulcer 3.8% (placebo 0%) back pain 3.8% (placebo 2.6%) colitis 3.8% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 5 mg nasopharyngitis 15.4% (placebo 2.6%) asthma 7.7% (placebo 0%) covid-19 7.7% (placebo 2.6%) NCT03199053 · Phase 3 · registry result, not featured evidence · combination 2.5 mg vitamin d deficiency 4.5% (placebo 6.6%) nausea 3.4% (placebo 0%) urinary tract infection 3.4% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg influenza 4.9% (placebo 2.6%) bronchitis 1.6% (placebo 0%) chronic sinusitis 1.6% (placebo 0%) NCT03199053 · Phase 3 · registry result, not featured evidence 2.5 mg covid-19 6.6% (placebo 2.6%) upper respiratory tract infection 6.6% (placebo 2.6%) urinary tract infection 4.9% (placebo 5.3%) NCT03199053 · Phase 3 · registry result, not featured evidence dapagliflozin 10 mg, saxagliptin 5 mg urinary tract infection 13.7% upper respiratory tract infection 10.1% headache 7.9% NCT02419612 · Phase 3 · registry result, not featured evidence viral upper respiratory tract infection 7.7% upper respiratory tract infection 5.2% headache 3.7% NCT02551874 · Phase 3 · registry result, not featured evidence · combination glomerular filtration rate decreased 4.1% pollakiuria 2.4% urinary tract infection 2.4% NCT02681094 · Phase 3 · registry result, not featured evidence · add on nasopharyngitis 7.8% headache 5.6% urinary tract infection 4.3% NCT02284893 · Phase 3 · registry result, not featured evidence · combination oropharyngeal pain 50% (placebo 25%) acne 25% (placebo 0%) cough 25% (placebo 25%) NCT01204775 · Phase 3 · registry result, not featured evidence headache 50% (placebo 0%) abdominal pain upper 25% (placebo 0%) back pain 25% (placebo 0%) NCT01434186 · Phase 3 · registry result, not featured evidence 5 mg QD hypoglycaemia 21.8% (placebo 23.8%) upper respiratory tract infection 2.6% (placebo 4.3%) urinary tract infection 2.6% (placebo 0.9%) NCT02104804 · Phase 3 · registry result, not featured evidence · combination urinary tract infection 9.4% (placebo 10%) influenza 7.5% (placebo 7.5%) headache 6.9% (placebo 8.1%) NCT01646320 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.2% (placebo 6.8%) headache 5.9% (placebo 7.4%) nasopharyngitis 5.9% (placebo 4.9%) NCT01619059 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 6.2% (placebo 9.4%) diarrhoea 5.4% (placebo 3.9%) hypertension 5.4% (placebo 1.6%) NCT01128153 · Phase 3 · registry result, not featured evidence diarrhoea 5.8% urinary tract infection 5.1% nasopharyngitis 4.3% NCT00960076 · Phase 3 · registry result, not featured evidence · combination nasopharyngitis 10.7% diarrhoea 5.8% upper respiratory tract infection 5.8% NCT00575588 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 8.4% (placebo 9.4%) NCT00918879 · Phase 3 · registry result, not featured evidence 5 mg + Metformin XR 1500 mg cough 6.5% NCT00918138 · Phase 3 · registry result, not featured evidence · combination 5 mg urinary tract infection 7.6% (placebo 7.9%) nasopharyngitis 6.3% (placebo 6.6%) upper respiratory tract infection 6.3% (placebo 7.3%) NCT00757588 · Phase 3 · registry result, not featured evidence · combination hypoglycaemia 28.2% (placebo 29.4%) anaemia 5.9% (placebo 8.2%) hypertension 5.9% (placebo 5.9%) NCT00614939 · Phase 3 · registry result, not featured evidence 5 mg headache 25% (placebo 18.8%) muscle spasms 25% (placebo 0%) infusion site pain 20% (placebo 12.5%) NCT00374907 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.3% (placebo 7.7%) NCT00698932 · Phase 3 · registry result, not featured evidence 5 mg upper respiratory tract infection 6.7% (placebo 4.5%) NCT00661362 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for 38 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Saxagliptin
show 8 more results
show 6 more results
show 15 more results
show 3 more results
show 4 more results
show 2 more results
show 7 more results
show 11 more results
show 2 more results
show 1 more result
+ 49 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Saxagliptin's landscape